JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.C500082200 on March 21, 2005

J. Biol. Chem., Vol. 280, Issue 19, 18573-18578, May 13, 2005
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
280/19/18573    most recent
C500082200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kobayashi, M.
Right arrow Articles by Uchiyama, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kobayashi, M.
Right arrow Articles by Uchiyama, T.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Ubiquitination of APOBEC3G by an HIV-1 Vif-Cullin5-Elongin B-Elongin C Complex Is Essential for Vif Function*

Masayuki Kobayashi, Akifumi Takaori-Kondo{ddagger}, Yasuhiro Miyauchi, Kazuhiro Iwai, and Takashi Uchiyama

From the Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawaracho, Sakyo-ku, Kyoto 606-8507, the Department of Molecular Cell Biology, Graduate School of Medicine, Osaka City University, Osaka 545-8585, and CREST, Japan Science and Technology Corporation (JST), Kawaguchi, Saitama 332-0012, Japan

The human immunodeficiency virus type 1 (HIV-1) virion infectivity factor (Vif) overcomes the antiviral activity of APOBEC3G to protect HIV-1 DNA from G-to-A hypermutation. Vif targets APOBEC3G for ubiquitination and proteasomal degradation by forming an SCF-like E3 ubiquitin ligase complex composed of Cullin5, Elongin B, and Elongin C (Vif-BC-Cul5) through a novel SOCS-box motif. In this paper, we have established an in vitro ubiquitin conjugation assay with purified Vif-BC-Cul5 complex and reported that the Vif-BC-Cul5 complex could function as an E3 ligase for APOBEC3G in vitro. A Vif-BC-Cul5 complex promotes the in vitro ubiquitination of the wild type, APOBEC3G but not that of D128K mutant, which does not interact with Vif. We have also investigated several loss-of-function Vif mutants. One mutant, SLQ144/146AAA, lost its activity on APOBEC3G because it could not form a complex due to mutations in SOCS-box motif. Other mutants, C114S and C133S, also lost their activity because of loss of the E3 ligase activity of a Vif-BC-Cul5 complex, although these mutants retained the ability to bind to APOBEC3G as well as Cul5 complex. These findings suggest that the E3 ubiquitin ligase activity of the Vif-BC-Cul5 complex is essential for Vif function against APOBEC3G.


Received for publication, March 1, 2005 , and in revised form, March 18, 2005.

* This work was supported in part by grants-in-aid from the Ministry of Education, Culture, Sports, Science, and Technology, Japan. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

{ddagger} To whom correspondence should be addressed. Tel.: 81-75-751-3152; Fax: 81-75-751-4963; E-mail: atakaori{at}kuhp.kyoto-u.ac.jp.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
J. Virol.Home page
M. Marin, S. Golem, K. M. Rose, S. L. Kozak, and D. Kabat
Human Immunodeficiency Virus Type 1 Vif Functionally Interacts with Diverse APOBEC3 Cytidine Deaminases and Moves with Them between Cytoplasmic Sites of mRNA Metabolism
J. Virol., January 15, 2008; 82(2): 987 - 998.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
C. A. Virgen and T. Hatziioannou
Antiretroviral Activity and Vif Sensitivity of Rhesus Macaque APOBEC3 Proteins
J. Virol., December 15, 2007; 81(24): 13932 - 13937.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
T. Wang, C. Tian, W. Zhang, K. Luo, P. T. N. Sarkis, L. Yu, B. Liu, Y. Yu, and X.-F. Yu
7SL RNA Mediates Virion Packaging of the Antiviral Cytidine Deaminase APOBEC3G
J. Virol., December 1, 2007; 81(23): 13112 - 13124.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. Bernacchi, S. Henriet, P. Dumas, J.-C. Paillart, and R. Marquet
RNA and DNA Binding Properties of HIV-1 Vif Protein: A FLUORESCENCE STUDY
J. Biol. Chem., September 7, 2007; 282(36): 26361 - 26368.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
R. A. Russell and V. K. Pathak
Identification of Two Distinct Human Immunodeficiency Virus Type 1 Vif Determinants Critical for Interactions with Human APOBEC3G and APOBEC3F
J. Virol., August 1, 2007; 81(15): 8201 - 8210.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
K. Luo, T. Wang, B. Liu, C. Tian, Z. Xiao, J. Kappes, and X.-F. Yu
Cytidine Deaminases APOBEC3G and APOBEC3F Interact with Human Immunodeficiency Virus Type 1 Integrase and Inhibit Proviral DNA Formation
J. Virol., July 1, 2007; 81(13): 7238 - 7248.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
J. L. Mbisa, R. Barr, J. A. Thomas, N. Vandegraaff, I. J. Dorweiler, E. S. Svarovskaia, W. L. Brown, L. M. Mansky, R. J. Gorelick, R. S. Harris, et al.
Human Immunodeficiency Virus Type 1 cDNAs Produced in the Presence of APOBEC3G Exhibit Defects in Plus-Strand DNA Transfer and Integration
J. Virol., July 1, 2007; 81(13): 7099 - 7110.
[Abstract] [Full Text] [PDF]


Home page
FASEB J.Home page
Z. Xiao, E. Ehrlich, K. Luo, Y. Xiong, and X.-F. Yu
Zinc chelation inhibits HIV Vif activity and liberates antiviral function of the cytidine deaminase APOBEC3G
FASEB J, January 1, 2007; 21(1): 217 - 222.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
C. Tian, X. Yu, W. Zhang, T. Wang, R. Xu, and X.-F. Yu
Differential Requirement for Conserved Tryptophans in Human Immunodeficiency Virus Type 1 Vif for the Selective Suppression of APOBEC3G and APOBEC3F
J. Virol., March 15, 2006; 80(6): 3112 - 3115.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2005 by the American Society for Biochemistry and Molecular Biology.